L
Linde A. Miles
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 27
Citations - 1942
Linde A. Miles is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myeloid. The author has an hindex of 11, co-authored 20 publications receiving 1212 citations. Previous affiliations of Linde A. Miles include Johns Hopkins University & Pennsylvania State University.
Papers
More filters
Journal ArticleDOI
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao,Rona Yaeger,Vanessa Rodrik-Outmezguine,Anthony Tao,Neilawattie M. Torres,Matthew T. Chang,Matthew T. Chang,Matthias Drosten,Huiyong Zhao,Fabiola Cecchi,Todd Hembrough,Judith Michels,Judith Michels,Hervé Baumert,Linde A. Miles,Linde A. Miles,Naomi Campbell,Elisa de Stanchina,David B. Solit,Mariano Barbacid,Barry S. Taylor,Neal Rosen +21 more
TL;DR: Three distinct functional classes of BRAF mutants in human tumours are defined—those that have impaired kinase activity or are kinase-dead, whose activation of signalling is RAS-dependent, and those that activate ERK signalling by different mechanisms that dictate their sensitivity to therapeutic inhibitors of the pathway.
Journal ArticleDOI
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner,Eric E. Gardner,Benjamin H. Lok,Valentina E. Schneeberger,Patrice Desmeules,Linde A. Miles,Paige K. Arnold,Andy Ni,Inna Khodos,Elisa de Stanchina,Thuyen Nguyen,Julien Sage,John Campbell,Scott Ribich,Natasha Rekhtman,Afshin Dowlati,Pierre P. Massion,Charles M. Rudin,Charles M. Rudin,John T. Poirier +19 more
TL;DR: Inclusion of an EZH2 inhibitor with standard cytotoxic therapies prevented emergence of acquired resistance and augmented chemotherapeutic efficacy in both chemosensitive and chemoresistant models of small cell lung cancer.
Journal ArticleDOI
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf,Nadine Jahchan,Peter J. Schnorr,Sandra Cristea,Aaron M. Ring,Roy Louis Maute,Anne Kathrin Volkmer,Jens Peter Volkmer,Jie Liu,Jing Shan Lim,Dian Yang,Garrett Seitz,Thuyen Nguyen,Di Wu,Kevin Jude,Heather Guerston,Amira A. Barkal,Francesca Trapani,Julie George,John T. Poirier,Eric E. Gardner,Linde A. Miles,Elisa de Stanchina,Shane Lofgren,Hannes Vogel,Monte M. Winslow,Caroline Dive,Roman K. Thomas,Charles M. Rudin,Matt van de Rijn,Ravindra Majeti,K. Christopher Garcia,Irving L. Weissman,Julien Sage +33 more
TL;DR: Disruption of the interaction of CD47 with SIRPα using anti-CD47 antibodies induced macrophage-mediated phagocytosis of human SCLC patient cells in culture, and this approach could enable personalized immunotherapeutic regimens in patients with S CLC and other cancers.
Journal ArticleDOI
Single-cell mutation analysis of clonal evolution in myeloid malignancies.
Linde A. Miles,Robert L. Bowman,Tiffany R. Merlinsky,Isabelle S. Csete,Aik Ooi,Robert Durruthy-Durruthy,Michael Bowman,Christopher Famulare,Minal Patel,Pedro Mendez,Chrysanthi Ainali,Benjamin Demaree,Cyrille L. Delley,Adam R. Abate,Manimozhi Manivannan,Sombeet Sahu,Aaron D Goldberg,Kelly L. Bolton,Ahmet Zehir,Raajit K. Rampal,Martin Carroll,Sara E. Meyer,Aaron D. Viny,Ross L. Levine +23 more
TL;DR: Single cell clonal architecture provides novel insights into the pathogenesis of myeloid transformation and how clonal complexity evolves with disease progression and is combined with mutational analysis to map somatic genotype and clonal Architecture with immunophenotype.
Journal ArticleDOI
Substrate positioning controls the partition between halogenation and hydroxylation in the aliphatic halogenase, SyrB2
Megan L. Matthews,Christopher S. Neumann,Linde A. Miles,Tyler L. Grove,Squire J. Booker,Carsten Krebs,Christopher T. Walsh,J. Martin Bollinger +7 more
TL;DR: It is shown that positioning of the alkyl group of the substrate away from the oxo/hydroxo ligand and closer to the halogen ligand sacrifices H-abstraction proficiency for halogen-rebound selectivity, and substrate-intermediate disposition and the carboxylate → halide ligand swap combine to specify theHalogenation outcome.